Drilldown: Medicines

Other values:

Search

None (78) · (none, never marketed) (1) · Dalmane (1) · Delysid (historical, Sandoz, withdrawn 1965) (1) · Doral (1) · Doriden (1) · GoLYTELY, NuLYTELY, TriLyte, MoviPrep, Plenvu, Gavilyte (1) · Halcion (1) · Hetlioz (1) · Imovane (1) · Kristalose, Constulose, Generlac, Enulose (1) · Lunesta (1) · MiraLAX (OTC), GlycoLax, GoLYTELY (with electrolytes for bowel prep), CoLyte, MoviPrep, NuLYTELY (1) · Mogadon (1) · Nembutal (1) · Placidyl (1) · ProSom (1) · Quaalude (1) · Restoril (1) · Rohypnol (1) · Rozerem (1) · Seconal (1) · Sonata (1) · THIP (1) · Versed (1) · Xyrem (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antiparkinsonian · Antipsychotic · Empathogen · Neuroleptic · Cathinone

Other values:

Search

5-HT2A agonist (26) · GABAA positive allosteric modulator (15) · Potent 5-HT2A agonist (5) · LSD analogue; 5-HT2A agonist (4) · Prodrug of LSD; 5-HT2A agonist (4) · None (3) · GABAA positive allosteric modulator (non-benzodiazepine) (3) · Contains LSA (2) · Contains mescaline (2) · GABAA potentiator and direct activator (2) · Melatonin receptor agonist (2)

Other values:

Search

None (99) · No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies. (1) · '"`UNIQ--vote-00000056-QINU`"', '"`UNIQ--vote-00000057-QINU`"' (1) · '"`UNIQ--vote-00000F5C-QINU`"', '"`UNIQ--vote-00000F5D-QINU`"' (1) · '"`UNIQ--vote-0000132E-QINU`"', '"`UNIQ--vote-0000132F-QINU`"', '"`UNIQ--vote-00001330-QINU`"' (1)

None (99) · 4 L oral solution (GoLYTELY-class) split-dose: 2 L evening before, 2 L morning of procedure; low-volume products (MoviPrep, Plenvu) use 1-2 L with required clear-fluid intake (1) · Constipation: 15-30 mL PO daily (titrate to 1-2 soft stools/day); hepatic encephalopathy: 20-30 g (30-45 mL) PO/PR every 1-2 hours acutely until soft stools, then BID-QID to target 2-3 soft stools/day (1) · Constipation: 17 g (one capful) PO daily dissolved in 4-8 oz fluid; bowel prep: 4 L of PEG-electrolyte solution split-dose evening before and morning of procedure (1) · No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam). (1)

None (99) · 10 g/15 mL solution (Constulose); 10 g, 20 g powder packets (Kristalose) (1) · 17 g (OTC) and 14 g (Rx) powder packets; 238, 510, 527 g bottles; PEG-electrolyte preparations 4 L (GoLYTELY, NuLYTELY) (1) · Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists. (1) · Powder for oral solution in 4 L jugs (PEG 3350 ~236 g + NaCl, NaHCO3, KCl, Na2SO4) and low-volume packets (1)

None (99) · 4 L per procedure (standard-volume products) (1) · Indication-specific; bowel prep regimens reach 4 L cumulative (1) · Indication-specific; HE may require high-volume dosing (1) · N/A (never approved) (1)

None (98) · especially in acute HE) (1) · intranasal; rectal and IV reported. (1) · Oral (5) · rectal (enema (1) · sublingual (1)

None (98) · 30–60 minutes (1) · Constipation: 1-3 days; bowel prep: 1-3 hours after starting (1) · Constipation: 24-48 hours; HE: ammonia reduction within hours of stool production (1) · First bowel movement within 1-2 hours (1) · ~20–40 min PO; faster sublingual/intranasal. (1)

None (98) · 4-6 hours (1) · 6–10 h subjective; full pharmacologic effect considerably longer. (1) · 8–12 hours (1) · Hours (2)

None (98) · 3–5 hours (1) · Estimated ~12–17 h (some sources cite up to ~21 h); active metabolites prolong effect. (1) · Not absorbed (1) · Not meaningfully described (negligible systemic absorption) (1) · Not meaningfully described — lactulose is not significantly absorbed (1)

None (98) · 70–90% (oral) (1) · <0.1% systemic absorption (PEG 3350 is too large to absorb intact) (1) · <3% systemic absorption (the basis of the safety and mechanism)'"`UNIQ--ref-00000F5E-QINU`"' (1) · Negligible (not absorbed)'"`UNIQ--ref-00000058-QINU`"' (1) · Not formally characterized in humans. (1)

None (98) · Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data, assume worst-case. (1) · Generally considered safe (minimal systemic absorption).<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Generally considered safe due to minimal systemic absorption.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Not absorbed; generally considered acceptable when bowel prep is required<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Not established (1)

None (99) · OTC (MiraLAX) and [[USLegal:Prescription only|Rx-only]] (electrolyte solutions for bowel prep) in US (1) · Schedule I (United States) (1) · [[USLegal:Prescription only|Rx-only]] in US (1) · [[USLegal:Prescription only|Rx-only]] in US (most products; some low-volume packs OTC) (1)